Health care resource utilization among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) was examined in a population-level study presented at the American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting (AAO-HNSF 2021).
Study authors conducted a retrospective analysis of the IBM Health MarketScan Research Databases over a 5-year period to identify adult and pediatric patients with newly diagnosed chronic rhinosinusitis without nasal polyps (CRSsNP) or CRSwNP with 2 years of continuous follow-up enrollment data (N=238,825). They analyzed health care resource utilization between CRSsNP and CRSwNP groups in terms of prescriptions, sinus surgeries, outpatient visits, and overall costs.
Overall, 7.8% of patients (n=18,590) had CRSwNP. The CRSwNP cohort had a higher prevalence of asthma (21.2% vs 13.6%, respectively) and allergies (41.5% vs 31.2%, respectively) compared with the CRSsNP cohort. With regard to pharmacotherapy, patients in the CRSwNP and CRSsNP received a similar amount of antibiotics (92.1% vs 95.7%, respectively), prescriptions (median 5.0 vs 4.0, respectively, over 2 years), and topical or oral steroids (74.9% vs 73.4%, respectively).
Results also indicated that patients in the CRSwNP cohort had a higher surgery rate compared with those in the CRSsNP cohort (41.6% vs 7.9%, respectively), which contributed to the overall higher mean costs ($6144.1 vs $2027.9, respectively).
Study authors concluded that the “overall cost associated with CRSwNP was likely due to the high rate of sinus surgery in addition to outpatient medical therapy.” Quality improvements will largely be dependent on educating clinicians on reducing the use of antibiotics and increasing the use of steroids in patients with CRSwNP, they added.
Frisco N, Lee HJ, Jang D. Treatment of chronic rhinosinusitis with nasal polyps: a population-based analysis. Presented at: AAO-HNS 2021 Annual Meeting; October 3-6, 2021; Los Angeles, CA.
This article originally appeared on MPR